<DOC>
	<DOC>NCT01221545</DOC>
	<brief_summary>The purpose of this study is to investigate safety and tolerability after high Single Ascending Oral Doses of AZD1656.</brief_summary>
	<brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Provision of signed and dated, written informed consent prior to any study specific procedures. Male, T2DM patients aged 2060 years Treatment with 1 to 2 OADs as Therapy for T2DM for at least 30 days prior to enrollment Patients should not have been treated with glitazones within 6 months prior to enrollment Male T2DM patients without known cardiovascular disease, with the exception of Grade 1 hypertension without secondary organ involvement (eg. grade 1 HT is allowed if no eye, kidney disease or LVH has been documented). History of ischemic heart disease , heart failure, stroke, transitory ischemic attack or peripheral vascular disease. Prolonged QTcF&gt;450 msec or shortened QTcF&lt;350 msec or family history of long QT syndrome. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. Systolic BP&gt;159 mmHg or diastolic BP&gt;99 mmHg at screening and on Day1</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Diabetes Mellitus</keyword>
</DOC>